Cargando…

Correction: Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico

Detalles Bibliográficos
Autores principales:	Rosenthal, Joseph, Belfort, Georges, Isaacson, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878765/ https://www.ncbi.nlm.nih.gov/pubmed/27219661 http://dx.doi.org/10.1371/journal.pone.0156474

Ejemplares similares

Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico
por: Rosenthal, Joseph, et al.
Publicado: (2016)

Correction: treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice
por: LaClair, Katherine D, et al.
Publicado: (2013)

Bexarotene treatment does not clear β-Amyloid in an AD mouse model and Beagle dogs
por: Tesseur, Ina, et al.
Publicado: (2013)

Interaction of Amyloid Inhibitor Proteins with Amyloid Beta Peptides: Insight from Molecular Dynamics Simulations
por: Das, Payel, et al.
Publicado: (2014)

Correction: Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer’s disease
por: Okamato, Masahiro, et al.
Publicado: (2019)

Correction to: Comprehensive characterization of elevated tau PET signal in the absence of amyloid-beta
Publicado: (2023)

A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats
por: Ren, Shuyue, et al.
Publicado: (2020)

Photodegradation of Bexarotene and Its Implication for Cytotoxicity
por: Kryczyk-Poprawa, Agata, et al.
Publicado: (2021)

Correction: Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates
por: Ruiz, Agustín, et al.
Publicado: (2014)

Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma
por: Morita, Akimichi, et al.
Publicado: (2022)

Correction: A glycine zipper motif mediates the formation of toxic beta-amyloid oligomers in vitro and in vivo
por: Fonte, Virginia, et al.
Publicado: (2014)

Correction: Competitive Mirror Image Phage Display Derived Peptide Modulates Amyloid Beta Aggregation and Toxicity
por: Rudolph, Stephan, et al.
Publicado: (2016)

The utility of bexarotene in mycosis fungoides and Sézary syndrome
por: Panchal, Manisha R, et al.
Publicado: (2015)

Preclinical PET Neuroimaging of [(11)C]Bexarotene
por: Rotstein, Benjamin H., et al.
Publicado: (2016)

Bexarotene-Induced Hypertriglyceridemia: A Case Report
por: Maminakis, Chris, et al.
Publicado: (2018)

A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects
por: Ghosal, Kaushik, et al.
Publicado: (2016)

Correction: Metabolomics and In-Silico Analysis Reveal Critical Energy Deregulations in Animal Models of Parkinson’s Disease
Publicado: (2014)

Correction to: NLRP3-dependent microglial training impaired the clearance of amyloid-beta and aggravated the cognitive decline in Alzheimer’s disease
por: He, Xiao-fei, et al.
Publicado: (2022)

Bexarotene Reduces Blood-Brain Barrier Permeability in Cerebral Ischemia-Reperfusion Injured Rats
por: Xu, Lu, et al.
Publicado: (2015)

The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
por: Tousi, Babak
Publicado: (2015)

Identification of Bexarotene as a PPARγ Antagonist with HDX
por: Marciano, David P., et al.
Publicado: (2015)

Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas
por: Warda, Ankedo, et al.
Publicado: (2023)

Fullerenemalonates inhibit amyloid beta aggregation, in vitro and in silico evaluation
por: Melchor, Martínez-Herrera, et al.
Publicado: (2018)

Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma
por: Tanita, Kayo, et al.
Publicado: (2019)

Effectiveness of combined bexarotene and excimer laser treatment for folliculotropic mycosis fungoides
por: Furukawa, Fumina, et al.
Publicado: (2021)

Systematic in silico analysis of clinically tested drugs for reducing amyloid‐beta plaque accumulation in Alzheimer's disease
por: Madrasi, Kumpal, et al.
Publicado: (2021)

Publisher Correction: Crocus-derived compounds alter the aggregation pathway of Alzheimer’s Disease - associated beta amyloid protein
por: Koulakiotis, Nikolaos Stavros, et al.
Publicado: (2021)

Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study
por: Sakr, Fatemah A., et al.
Publicado: (2022)

Correction: Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
por: Qiao, Wenhui, et al.
Publicado: (2023)

Bexarotene Gel: A New Topical Therapy for Alopecia Areata
por: Rajiv, Mahajan, et al.
Publicado: (2010)

Bexarotene: A Rare Cause of Misleading Thyroid Function Tests
por: Pattan, Vishwanath, et al.
Publicado: (2020)

Cocrystal Prediction of Bexarotene by Graph Convolution Network and Bioavailability Improvement
por: Xiao, Fu, et al.
Publicado: (2022)

FRI511 Bexarotene: A Deceptive Cause Of Iatrogenic Hypothyroidism
por: Ghaith, Sarah, et al.
Publicado: (2023)

Correction to: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy
por: De Kort, Anna M., et al.
Publicado: (2021)

Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma
por: Illidge, T, et al.
Publicado: (2013)

Correction to: Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden
por: Femel, Julia, et al.
Publicado: (2022)

Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020)

Correction to: Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer’s disease
por: Ortner, Marion, et al.
Publicado: (2020)

Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
por: Au, Trang H., et al.
Publicado: (2021)

High-Dose Thyroid Hormone Replacement in Bexarotene-Induced Central Hypothyroidism
por: Mathews, Tony, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eqp52f908q8aiv75pabdrnti32